e on theoretical statistical safety concerns. 4 EFTA_R1_01558196 EFTA02455523 An FDA committee has recommended that the agency deny approval for Sarepta Therapeutics new drug Eteplirsen, a potentially lifesaving drug for Duchenne Muscular dystrophy, a rare and invariably fatal disease that affects young boys. Th